Metropolis Healthcare reports ~16% YoY revenue growth in Q1FY27
Metropolis Healthcare Ltd released a business update for the quarter ended June 30, 2026 (Q1FY27). The company said its consolidated revenue grew about 16% compared to the same quarter last year. Higher patient volumes and a shift toward more expensive tests drove the growth. EBITDA margins improved year‑on‑year, in line with what management had said earlier. Margins remained roughly the same as the previous quarter. The update did not give exact revenue, profit, or margin numbers. A detailed, audited financial statement will come later after the board approves it.
Company profile
How revenue grew 16%
This growth rate is at the upper end of the company’s three‑year target – a 14‑15% revenue growth per year, with 8‑9% from more patients and about 5% from better test mix (and small price hikes if needed) . The Q1FY27 performance, driven by volumes and a richer mix, matches that plan.
How Metropolis plans to keep growing
- Growing patient volumes: The company is adding 1,500 asset‑light collection centres over three years, lifting the lab‑to‑centre ratio from 1:24 to 1:35. It is also building 100 “mini hubs” (upgraded existing centres plus new ones) that offer pathology plus basic radiology (X‑ray, ECG, sonography). The focus has shifted to “throughput‑led productivity” – getting more samples processed through existing labs. Digital channels (app, website) now contribute ~25% of revenue with higher customer lifetime value and lower cost. For FY27, management guided “about 8% to 9% of patient volume growth” .
- Growing package size (revenue per patient): The fastest‑growing areas are TruHealth wellness and specialty testing. TruHealth grew 20‑21% organically in FY26; specialty (including genomics) grew 16‑17%. TruHealth already contributes 18% of revenue and is expected to exceed 25% within 2‑3 years by adding more services. Specialty contributes 39% of revenue, with genomics seen as a “significant growth driver” over time. Revenue per patient growth is driven by a better test mix, not by raising prices – though price increases remain an option later in the year if needed .
- Why patients choose Metropolis: Management says trust in quality, scientific expertise, and consistent results are the main reasons. Ameera Shah, Chairperson, noted: “We are seeing a steady shift towards organized trusted players like Metropolis, as doctors and consumers are placing greater emphasis on quality standards, scientific expertise, lab compliance, and an overall superior experience.” The company’s capabilities – consistent lab quality, deep doctor engagement, strong clinical expertise, tech platforms, and a standardised operating model – are “difficult to replicate at scale” .
- Recent acquisitions (Core Diagnostics, Scientific Pathology, Dr. Ahuja’s, Ambika Pathology) continue to add to revenue, and their integration is on track .
Margins on track: better than last year, stable vs. last quarter
What the available revenue and profit figures show
Revenue and PAT (₹ crore)
Revenue moved from ₹345 crore in Q4FY25 to a quarterly range of ₹386‑429 crore in FY26. PAT rose from ₹29 crore in Q4FY25 to ₹42‑53 crore per quarter in FY26. The Q1FY27 growth commentary points to continued expansion, but absolute numbers will come with the audited statement .
Management views: strong tailwinds, no price hike planned
On pricing, the company did not raise prices in Q4FY26 and, as of May 2026, was not planning a price hike for FY27. However, Managing Director Surendran Chemmenkotil kept the door open: “as the year progresses, if there is a need for us to do it, we would not hesitate to do so” . So the Q1FY27 growth appears to be organic – from higher volumes and a better test mix, not from higher list prices.
What to watch
---
Sources
- 1 Financial statement analysis
- 2 Earnings-call transcript, May 2026
- 3 announcement_category · neutral · value 0.050000
- 4 Business Update For Q1FY27
- 5 Metropolis Healthcare Ltd - 542650 - Business Update For Q4FY26